Primary operational goal for 2025 is to enter into multiple licensing agreements for human diagnostic applications, particularly cancer & sepsis, emulating the strategy employed with the Nu.Q Veterinary Canine Cancer Test Another prong is to utilize the CE Mark certification to expand the use of the Nu.Q H3.1 NETs assay under its broad claim for detecting and monitoring diseases with a NETs component. Progress reported in pre-analytic paper on nucleosome detection in cats required prior to clinical study for the detection of feline lymphoma.
